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Higher MSEs found in indirect mapping were mostly pronounced in lower utilities 
(<0.2). Predicted utilities were slightly higher than actual values when population 
average was used for input (0.3–3%). Similar ﬁ ndings were noted in sub-samples. 
CONCLUSIONS: Both methods produced robust results. Compared to direct 
mapping, indirect mapping better represents the EQ-5D’s descriptive information, 
although with higher MSE/MAE. This research provides algorithms for estimating 
EQ-5D item responses and utilities on the basis of pain scores in absence of direct 
utility evidence. Further investigation using out-of-sample predictions is encouraged.
PSY68
HEPATITIS C-SPECIFIC QUALITY OF LIFE IS NOT PROPERLY 
MEASURED BY EXISTING INSTRUMENTS
Duracinsky M, Armstrong AR, Lalanne C, Chassany O
Assistance Publique-Hopitaux de Paris, Paris, France
OBJECTIVES: Measures commonly used in Hepatitis C (HCV) Health-Related 
Quality of Life (HRQL) research were investigated to determine whether they effec-
tively encompass the disease-speciﬁ c experience of HCV. METHODS: Important 
HCV HRQL dimensions were identiﬁ ed via a review of qualitative and quantitative 
literature. Medline and Embase were interrogated for appropriate studies. Quality and 
relevance of HCV HRQL studies were assessed against FDA and EMEA guidelines. 
The review facilitated construction of a conceptual framework of HCV HRQL. The 
framework was compared against HRQL measures used in HCV research, including 
the SF-36, Hepatitis Quality of Life Questionnaire (HQLQ), Chronic Liver Disease 
Questionnaire (CLDQ), Liver Disease Symptom Index (LDSI 2.0), and Hepatitis B 
Quality of Life instrument (HBQOL). RESULTS: Numerous dimensions encompassing 
the HCV HRQL experience were not adequately represented by common measures. 
Absent from the measures were consideration of treatment adherence and management, 
and management of side effects; HIV/HCV co-infection issues; drug addiction; resilience 
and coping; contagiousness and transmission-related issues; illness uncertainty and 
unpredictability; and changes in body image. HCV dimensions needing further attention 
were liver disease severity; psychiatric complications including emotional volatility; 
cognitive impairment during daily activity; sexual dysfunction; the multidimensional 
nature of stigma; and fatigue variability. CONCLUSIONS: The disease-speciﬁ c experi-
ence of HCV is not fully addressed by any single existing measure. An HCV HRQL 
instrument that is sensitive to the identiﬁ ed dimensions and issues would be of con-
siderable beneﬁ t. Such a measure would help health care providers plan individual 
interventions for problematic HRQL domains, as well as improve patient monitoring 
during treatment and clinical research trials, and contribute to determining the value 
and efﬁ cacy of treatment programs. 
URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies
PUK1
CONTRAST-INDUCED NEPHROPATHY IN PATIENTS WITH CHRONIC 
KIDNEY DISEASE UNDERGOING COMPUTED TOMOGRAPHY: A 
COMPARATIVE SAFETY META-ANALYSIS OF RANDOMIZED 
CONTROLLED TRIALS
Catalá-López F1, Arana E2
1Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain; 2Fundación 
Instituto de Investigación en Servicios de Salud, Valencia, Spain
OBJECTIVES: We conducted a systematic review and meta-analysis comparing the 
incidence of contrast-induced nephropathy (CIN) in patients at risk with chronic 
kidney disease (CKD) undergoing computed tomography (CT). METHODS: Random-
ized controlled clinical trials designated to evaluate the nephrotoxicity related to 
iso-osmolar contrast media (IOCM) compared to low-osmolar contrast media 
(LOCM) were searched in the following electronic databases: PubMed/MEDLINE, 
EMBASE, ISI Web of Knowledge and Virtual Health Library (BVS-BIREME), as well 
as abstracts presented at related scientiﬁ c societies meetings. Prior to data extraction, 
deﬁ nitions of nephrotoxicity were established. We applied a random effects model of 
DerSimonian and Laird, with heterogeneity (Q statistic), publication bias (Egger and 
Begg test) and sensitivity analyses. RESULTS: Five studies were included with 716 
randomized patients. When CIN was deﬁ ned as increased serum creatinine (SCr) ≥ 
25%, the relative risk (RR) was 0.71 (CI95% 0.40 to 1.26)—in favor of IOCM—and 
when it was deﬁ ned as SCr ≥ 0.5 mg/dL it showed a RR 1.48 (CI95% 0.37 to 5.87)—
favoring LOCM—in the four studies used this criterion. CONCLUSIONS: In patients 
with CKD undergoing CT there is a similar risk of CIN with the administration of 
any contrast media studied. CIN incidence depends on the chosen criteria and is lower 
with the deﬁ nition of SCr ≥ 0.5 mg/dL at 24–72 h.
PUK2
COMORBIDITY EFFECT ON HOSPITAL READMISSION RATES IN 
PATIENTS WITH RENAL FAILURE
Rhee Y1, Walker DR2, Inglese G2
1Northwestern University, Chicago, IL, USA; 2Baxter Healthcare Corporation, McGaw Park, 
IL, USA
OBJECTIVES: To examine the effects of comorbidities on the hospital readmission 
rate in renal failure (RF) patients on dialysis. METHODS: We used 2005–2007 U.S. 
MarketScan claims database to identify RF patients under 64 years old. RF dialysis 
patients were identiﬁ ed using ICD-9 and CPT codes. RF patients had to be continu-
ously eligible for at least 6 months after the initial dialysis diagnosis date (index dates). 
Comorbidity scores were measured by the Charlson Comorbidity Index (CCI). We 
identiﬁ ed readmission rates to the hospital within 15 days after the index date. 
ANOVA tests and logistic regression were performed to compare outcomes by CCI. 
RESULTS: A total of 6117 patients were diagnosed with RF. Among those who initi-
ated dialysis treatment, 13.9% and 86.1% were treated with peritoneal dialysis and 
hemodialysis, respectively. Over half of all patients were male (55.2%) and the average 
age was 52.4 years. The most frequent comorbid conditions were hypertension 
(69.1%), diabetes (34.5%), congestive heart failure (CHF) (26.3%), and anemia (26.4 
%). Most patients had low (78%, score < = 3) or moderate (12.0%, score 4–5) CCI 
scores. 7.2% of patients had a score of 6–7 and 125 (2.0%) had a score > 8. Older 
patients had signiﬁ cantly more severe CCI scores (P < 0.001). The average age in the 
moderate and severe co-morbidity groups was 51.7 and 57.4 years old, respectively. 
a total of 1.3% of RF dialysis patients were readmitted to the hospital within 15 days. 
Their readmission rates were signiﬁ cantly associated with the CCI score (P < 0.001). 
Patients over age 50 were signiﬁ cantly more likely to readmit to the hospital (P < 
0.001). Those with a higher CCI score were more likely to readmit to the hospital 
within 15 days (moderate group OR. 3.0, P < 0.001, very high group OR 4.04, P < 
0.001). CONCLUSIONS: For patients with RF, the presence of severe comorbid 
physical conditions was signiﬁ cantly associated with hospital readmission within 15 
days.
PUK3
ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH OVERACTIVE 
BLADDER (OAB) DISORDER: AN ELECTRONIC MEDICAL RECORD (EMR) 
DATA ANALYSIS
Asche C1, Kim J2, Chakravarti P3, Andersson KE4
1University of Utah College of Pharmacy, Salt Lake City, UT, USA; 2University of Utah, Salt 
Lake City, UT, USA; 3Novartis Pharmaceuticals, East Hanover, NJ, USA; 4Wake Forest 
University Baptist Medical Center, Winston-Salem, NC, USA
OBJECTIVES: To compare OAB patients to non-OAB patients by assessing their 
pre-existing comorbidities prior to their OAB diagnosis or ﬁ rst OAB treatment. 
METHODS: This retrospective cohort study used the General Electric (GE) Centricity 
EMR database. The study subjects were from between January 1, 1996 to March 30, 
2007. The index date for OAB patients was deﬁ ned as the date of their ﬁ rst prescrip-
tion for an antimuscarinic agent or a diagnosis for OAB identiﬁ ed by ICD-9 codes. 
The index date of non-OAB subjects without diagnosis or pharmacy claim was deﬁ ned 
as a year after the ﬁ rst activity date in the EMR. Subjects ≥18 years old were included 
and had 395 days of continuous enrollment before and after the index date. Non-OAB 
subjects were matched to OAB subjects on 1:1 propensity score matching based on 
age, body mass index (BMI) and gender at baseline. Two linear regressions were 
constructed using the outcome variables of the Charlson Comorbidity Index (CCI), 
using ICD-9 codes, and the Chronic Disease Score (CDS), using prescribed drugs, 
respectfully. RESULTS: There were 38,739 OAB subjects [mean age 61.18 (SD:13.26) 
years; 85.67% women] and 38,739 matched non-OAB subjects [mean age 61.17 (SD:
13.24) years; 85.70% women]. Patients with OAB had higher mean CCI and 
CDS than subjects without OAB [(CCI: 1.17 vs. 1.11 (p-value < 0.001); CDS: 
2.95 vs. 1.74 (p-value < 0.001)]. After controlling for other covariates, the linear 
regressions (n = 22,544) showed that OAB patients had higher CCI and CDS than 
subjects without OAB by 0.037 (p-value < 0.001) and by 0.881 (p-value: < 0.001), 
respectively. CONCLUSIONS: This study determined that pre-existing comorbidities 
were more prevalent in OAB patients than in non-OAB patients. These comorbidities 
should to be taken into account when making the decision on the most appropriate 
treatment option for each individual patient.
PUK4
A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE REGIMENS IN 
LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS
Kang MH, Kim HJ, Ko RK, Ko SK
Pﬁ zer Pharmaceuticals Korea Ltd., Seoul, South Korea
OBJECTIVES: In this study, we conducted a systematic review of three immunosup-
pressive regimens in lower risk renal transplantation and compared their efﬁ cacy. 
METHODS: MEDLINE were searched and two independent reviewers assessed 
studies. We limited the search to English, Randomized controlled trial, Human and 
publication between January 1, 1999~May 31, 2010. Studies which were conducted 
with adult renal transplant patients (>18 years) with lower immunological risk were 
included. Sirolimus + steroid regimen with 3 months cyclosporine, and CNI (Calci-
neurin inhibitor: cyclosporine or tacrolimus) regimen with MMF and steroid were 
eligible for inclusion. a total of 434 studies were retrieved from MEDLINE ﬁ rstly. By 
reviewing title, abstracts and full text, 10 studies were eligible for the inclusion ﬁ nally. 
As outcome data, we extracted patient survival and graft survival. RESULTS: There 
was no head-to-head clinical trial which compared the three regimens concurrently. 
But results from 2 studies shows trend of higher patient and graft survival with low 
dose CNI regimen than standard dose cyclosporine. ELITE-Symphony Study illus-
trated patient and graft survival of 96.5% and 89.3% for standard dose cyclosporine, 
98.2% and 93.1% for low dose cyclosporine, 97.2% and 94.2% for low dose tacro-
limus at 1 year. And CAESAR Study showed 97.1% and 92.4% for standard dose 
cyclosporine, 97.8% and 94.5% for low dose cyclosporine at 1 year. 5 reports from 
‘Rapamune Maintenance Regimen Study’ showed outcomes for sirolimus based 
regimen during 5 years. At 1 year, patient and graft survival were 98.1% and 97.2% 
and decreased thereafter. One study of tacrolimus based regimen reported 2-year 
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patient and graft survival of 92.9% and 92.4% for biopsy arm, 97.9% and 94.1% 
for control arm. Both of the treatment arms were standard dose tacrolimus regimen. 
CONCLUSIONS: Three of immunosuppressive regimens are considered to have 
similar efﬁ cacy in short-term patient and graft survival in lower immunological risk 
renal transplant patients.
PUK5
CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS IN 
RENAL REPLACEMENT THERAPY IN SÃO PAULO, BRAZIL
Takemoto ML, Fernandes RA, Passos RB, Tolentino ACM, Takemoto MM, Moretti AIP, 
Cukier FN
ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: This study aims to describe clinical and demographic characteristics 
of end-stage renal disease (ESRD) patients on renal replacement therapy in the São 
Paulo state, Brazil. METHODS: Cross-sectional analysis of São Paulo renal replace-
ment therapy claims as reported in Brazilian Ambulatory Information System (SIA/
DATASUS) database in January 2009. Repeated records were excluded using identi-
ﬁ cation code, age, sex, and ﬁ rst treatment date as compatibility criteria. The following 
variables were investigated: diseases associated to ESRD, anemia, glucose levels, HCV, 
HbSAg, HIV, urea reduction ratio (URR), vascular access, and type of renal replace-
ment therapy. RESULTS: A total of 18,360 patients were identiﬁ ed among 18,886 
available claims, with a mean age of 54.23 years (SD = 15.53) and 57.7% male. 
Among 8,305 patients for whom secondary ICD-10 codes in addition to those related 
to renal failure itself were available, the more frequent conditions associated to ESRD 
were diabetes mellitus (17.5%), hypertension (26.4%) and glomerulonephritis 
(8.81%). Continuous Ambulatory Peritoneal Dialysis (CAPD) was the therapeutic 
strategy for 9.9% of patients compared to hemodialysis in 90.1%. 58.4% of all 
patients had hemodialysis vascular access and 50.9% had URR > 65%. Prevalence of 
positive HCV, HbSAg and HIV serology tests was 4.3%, 0.9% and 0.6%, respectively. 
Anemia and glucose levels > 126 were present for 45.4% and 19.6% of patients. The 
total amount paid for renal replacement therapy procedures in January 2009 in São 
Paulo state was 36,073,377 BRL. CONCLUSIONS: Although diabetes and hyperten-
sion renal complications can be prevented, they accounted for 43.9% of all conditions 
related to renal disease among the studied population. The ﬁ ndings also indicate that 
CAPD is still underused in Brazilian health care public system compared to other 
countries, as reported by previous local studies.
PUK6
POST RENAL TRANSPLANT PATIENT SURVIVAL AND THE COMBINED 
ADVERSE EFFECT OF POOR RENAL FUNCTION AND NEW ONSET 
DIABETES MELLITUS
McEwan P1, Baboolal K2
1CRC, Cardiff, UK; 2Cardiff and Vale NHS Trust, Cardiff, UK
OBJECTIVES: A major challenge in the ﬁ eld of renal transplantation is to prolong 
patient survival. Previous studies have demonstrated that renal function at 1 year is a 
major determinant of long term patient survival. Furthermore, the development of 
new onset diabetes after transplantation identiﬁ es patients at high risk of cardiovas-
cular events and mortality. This study aims to quantify any additive effect of impaired 
renal function and elevated glucose levels at 1 year post transplant on patient mortal-
ity. METHODS: Consecutive renal transplants from a single UK transplant centre 
over a 10 year period were analyzed using multivariate logistic regression in SPlus 8; 
the risk of patient mortality was assessed after stratiﬁ cation by renal function (mea-
sured by glomerular ﬁ ltration rate (GFR)) and impaired fasting glucose levels. 
RESULTS: Data were available on 307 patients with fasting glucose and GFR mea-
surements at 1 year post transplant. Overall 37% (n = 114) had a GFR of less than 
40 mL/minute and of these, 24% (n = 27) had fasting glucose levels greater than 
7 mmol/L. After adjusting for age, sex and donor factors patients with fasting glucose 
greater than 7 mmol/L and a GFR less than 40 mL/minute had a mortality odds ratio 
of 5.47 (P < 0.01) compared to those with glucose levels less than 5.6 mmol/l and a 
GFR greater than 40 mL/minute. CONCLUSIONS: This study demonstrates that the 
development of impaired fasting glucose post transplants is associated with a 35% 
increase risk of mortality and the development of new onset diabetes associated with 
a 2-fold increased risk. Our study further suggests that there is a negative synergistic 
effect of deteriorating renal function and progressive impaired glucose regulations on 
patient survival. Consequently, therapeutic strategies that could both improve GFR at 
one year and the incidence of diabetes might be expected to improve long term patient 
survival. 
URINARY/KIDNEY DISORDERS – Cost Studies
PUK7
THE PHARMACY BUDGET IMPACT OF EXTENDING REIMBURSEMENT 
OF LANTHANUM CARBONATE TO TREATMENT OF 
HYPERPHOSPHATEMIA (>1.78 MMOL/L) IN PATIENTS WITH CHRONIC 
KIDNEY DISEASE PRE-DIALYSIS IN FRANCE AND THE UNITED 
KINGDOM
Campbell J1, Tao CY1, Keith MS2, Leahy KJ1, Russo L2
1i3 Innovus, Medford, MA, USA; 2Shire Pharmaceuticals, Wayne, PA, USA
OBJECTIVES: To examine the pharmacy budget impact (PBI) of extending reimburse-
ment of non-calcium lanthanum carbonate (LC) to treatment of hyperphosphatemia 
(serum phosphorus > 1.78 mmol/L) in patients with chronic kidney disease pre-dialysis 
(CKD-ND) in France and the UK over ﬁ ve years. METHODS: The treated prevalence 
of CKD-ND and hyperphosphatemia, and the use of pharmacologic therapies, were 
estimated using published literature and EU nephrologist surveys. Drug costs were 
estimated from published sources. Market share changes were estimated from market 
research. Base-case analyses assumed complete medication compliance. Annual PBI 
was calculated as the difference in total drug costs between scenarios with and without 
the reimbursement extension for LC. Alternate scenarios and deterministic sensitivity 
analyses were also estimated. RESULTS: A small percentage of CKD-ND patients, 
14,500 (7%) and 64,600 (14.6%), are estimated as hyperphosphatemic in France and 
the UK, respectively. Of these patients, 81% in France versus 30% in the UK are 
estimated to receive phosphate binder therapy. CKD-ND market share for LC is 
estimated at 12% in France and 1–2% in the UK. The label extension, adding hyper-
phosphatemic CKD-ND patients, is estimated to increase LC use primarily at the 
expense of calcium-based phosphate binders. The annual PBI from the label extension 
is estimated to grow over Years 1–5 from 0 to c1.1 M in France; and to be <£25,000 
in Years 1–5 in the UK. Results are most sensitive to LC market share changes post-
label extension. CONCLUSIONS: The number of CKD-ND patients with hyperphos-
phatemia (>1.78 mmol/L) eligible for LC treatment is minimal in France and the UK. 
Assuming complete compliance, the annual PBI after 5 years of a label extension for 
LC to CKD-ND patients is estimated to be c1.1 M in France and <£25,000 in the 
UK. Calcium is the predominant therapy in CKD-ND; however, adding LC may result 
in a low pharmacy budget impact.
PUK8
BUDGET IMPACT ANALYSIS OF ALISKIRENO IN TYPE 2 DIABETES 
PATIENTS WITH HYPERTENSION AND NEPHROPATHY IN THE 
MEXICAN INSTITUTE OF SOCIAL SECURITY
García-Contreras F1, Nevarez A1, Olvera K2
1Mexican Institute of Social Security, Mexico, D.F., Mexico; 2Novartis, Mexico, D.F., Mexico
OBJECTIVES: To determine the budget impact of Losartan + Aliskiren versus Losar-
tan in type 2 diabetes patients with hypertension and nephropathy in the Mexican 
Institute of Social Security (IMSS). METHODS: An annual budget impact analysis of 
the use of aliskiren in the treatment of diabetic nephropathy in the IMSS was made 
considering four scenarios: a) Losartan + Aliskireno; b) Losartan; c) real prevalence 
of diabetic nephropaty and d) estimated prevalence of diabetic nephropaty. The source 
of epidemiologic data was the Health National Survey (ENSA 2006). Information 
source to estimate health beneﬁ ts was AVOID study. Costing was performed through 
the technique of microcosting for replacement therapy with hemodialysis and perito-
neal dialysis. The use of resources was the standard IMSS supportive care, costs are 
in 2009 USD. There was no discount rate considered due to annual temporal horizon. 
a probabilistic and non-probabilistic sensitivity analysis was performed. RESULTS: 
Aliskiren alternative prevents the use of dialysis in the real scenario of 5,946 patients, 
with expected savings of $ 95,461,538.46 USD, while in the estimated alternative 
prevents dialysis in 11.765 with expected savings of $188,846,153.85 USD. CON-
CLUSIONS: Aliskiren use investment prevents up to 11,765 patients requiring dialysis 
with savings for the health sector of more than 188 million USD.
PUK9
REAL-LIFE DOSING OF ERYTHROPOIESIS-STIMULATING AGENTS 
(ESAS) IN CHRONIC KIDNEY DISEASE (CKD)-ASSOCIATED ANEMIA: 
BUDGET IMPACT
Walsh CM1, Bilton R1, Robinson JE2
1Complete Medical Group, Macclesﬁ eld, UK; 2BioTrends Research Group, Exton, PA, USA
OBJECTIVES: Effective management of chronic kidney disease (CKD)-associated 
anaemia has been established for all erythropoiesis-stimulating agents (ESAs). The aim 
of this study was to establish the real-life doses and comparative costs of both short-
acting ESAs and the newer longer-acting ESAs, darbepoetin alfa and the continuous 
erythropoietin receptor activator (C.E.R.A), and to forecast the impact of a change in 
current prescribing practice on health care budgets in Europe. METHODS: a retro-
spective chart review of CKD-associated anaemia management in 1014 pre-dialysis 
and 1016 dialysis patients was carried out by 261 nephrologists across the UK, Italy, 
Germany, Spain and France, between August 2008 and September 2009. Data col-
lected on ESA dosing were used to populate a UK budget impact model comparing 
current prescribing practice with speciﬁ c focus on C.E.R.A and darbepoetin alfa, over 
a ﬁ ve-year time horizon. Data on the number of patients, ESA market shares, and unit 
drug costs were derived from UK sources. RESULTS: The average monthly doses of 
ESAs in the combined ﬁ ve European markets (5EU) were as follows: epoetin alfa 
(pre-dialysis, 19,350 International Units (IU); dialysis, 35,404 IU); epoetin beta (pre-
dialysis, 18,230 IU; dialysis, 36,789 IU); darbepoetin alfa (pre-dialysis, 107 μg; dialy-
sis, 169 μg); C.E.R.A (pre-dialysis, 98 μg; dialysis, 150 μg). The model based on UK 
doses showed, that after ﬁ ve years, an increase in the use of C.E.R.A to 40% would 
reduce the overall ESA budget for CKD-associated anaemia by 15% compared to 
current prescribing practice. CONCLUSIONS: Based on real-life data, an increase in 
C.E.R.A prescribing may result in a cost-saving for the management of CKD-associ-
ated anaemia in the UK. This model can be applied to other European markets to 
forecast the local impact of a change in current prescribing practice.
